Major ag supplier Syngenta and biotech company Enko Chem are advancing research on a new mode of action (MoA) targeting fungal pathogens in cereal crops following the successful completion of their first year of field trials.
Founded in 2017, Enko developed a machine-learning-powered platform called Enkompass, which searches a library of molecules to identify compounds that can provide specific MoAs for crop diseases and pests, Anthony Klemm, CEO of Enko, told AgNavigator.
Since 2021, Enko has worked with Syngenta in a private capacity and revealed the discovery of this novel fungicide chemistry in January 2024. The following year, Enko and Syngenta started field trials, and now the two companies are taking the research to the next level through another round of field trials, Klemm explained.
Beyond its work with Syngenta, Enko identified a new fungicide target and associated chemistry and two novel fungicide modes, per an October press release.
Given its sensitivity to product development, field data on the molecule is not being released, but the two companies can confirm that the compound was benchmarked against existing fungicides and found to provide crop benefits, Klemm noted.
“Syngenta ran the field testing and evaluated this [chemistry] against leading compounds under a broad range of growing conditions, and so I would say that what we can validate is that the field data is backing up that the disease control has held up across all those regions that it was tested in, whether it be in Europe, in North or South America, or even in Asia,” Klemm elaborated.
How to develop new MoAs faster
Enko and Syngenta are advancing their work as demand for new crop protection products in response to a myriad of threats is on the rise and as plants develop resistance to chemicals. Also, crop protection companies like Syngenta are using technological advancements to save money and cut development expenses to bring these products to market faster.
Taking a new MoA from discovery through regulatory approval to a finished product typically costs $300 million and 13-14 years of development, Klemm noted. Enko is targeting a 75% reduction in time to discover new MoAs at a 90% lower price point over traditional research and development methods, he added.
“Those regulatory approvals, and the necessity to go through those to make sure we’re bringing safe compounds to the environment and to users, are crucial. And so, we need to look for spots through the development process where we can do things faster, more cost efficient, and have greater impact. We’re all about getting more shots on goal early,” Klemm elaborated.



